Anti-CD277 antibodies

Patent metadata

Field	Value
Publication number	US-10716838-B2
Application number	US-201916282733-A
Country	US
Kind code	B2
Filing date	Feb 22, 2019
Priority date	Dec 15, 2010
Publication date	Jul 21, 2020
Grant date	Jul 21, 2020

Abstract

Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

First claim

The invention claimed is:

1. An isolated anti-CD277 antibody, comprising the following CDRs:

Amino acid sequence

H-CDR1
RYYMY (SEQ ID NO: 27)

H-CDR2
EINPNNGGTKFNEKFKN(SEQ

ID NO: 28)

H-CDR3
EDDYDGTPFAMDY (SEQ ID

NO: 29)

L-CDR1
HASQNINVWLS(SEQ ID NO: 30)

L-CDR2
KASNLHT (SEQ ID NO: 31)

L-CDR3
QQGQTYPYT (SEQ ID NO: 32).

2. The anti-CD277 antibody of claim 1 , wherein said anti-CD277 antibody is a chimeric or humanized antibody.

3. An anti-CD277 antibody having the CDRs of mAb7.2, said mAb7.2 being obtained from the hybridoma accessible under CNCM deposit number I-4401.

4. The anti-CD277 antibody of claim 1 , wherein said anti-CD277 antibody is a murine antibody mAb7.2 as obtained from the hybridoma accessible under CNCM deposit number I-4401.

5. The anti-CD277 antibody of claim 1 , wherein said anti-CD277 antibody:
activates the cytolytic function, cytokine production and proliferation of Vγ9/Vδ2 T cells,
costimulates T cells together with CD3-TCR,
costimulates T cells in addition to CD28-B7 costimulation, and/or
increases the activity and/or survival of monocytes and dendritic cells.

6. A pharmaceutical composition comprising the anti-CD277 antibody of claim 1 , in combination with one or more pharmaceutically acceptable excipients.

7. The pharmaceutical composition of claim 6 , wherein said pharmaceutical composition is an injectable solution.

8. The pharmaceutical composition of claim 6 , wherein said pharmaceutical composition is formulated for intravenous or subcutaneous administration.

9. The anti-CD277 antibody of claim 3 , wherein said anti-CD277 antibody:
activates the cytolytic function, cytokine production and proliferation of Vγ9/Vδ2 T cells,
costimulates T cells together with CD3-TCR,
costimulates T cells in addition to CD28-B7 costimulation, and/or
increases the activity and/or survival of monocytes and dendritic cells.

10. A pharmaceutical composition comprising the anti-CD277 antibody of claim 3 , in combination with one or more pharmaceutically acceptable excipients.

11. The pharmaceutical composition of claim 10 , wherein said pharmaceutical composition is an injectable solution.

12. The pharmaceutical composition of claim 10 , wherein said pharmaceutical composition is formulated for intravenous or subcutaneous administration.

Assignees

• Olive Daniel
• Bonneville Marc
• Scotet Emmanuel
• Harly Christelle
• Guillaume Yves
• Inst Nat Sante Rech Med
• Inst Jean Paoli & Irene Calmettes
• Univ Aix Marseille
• Univ Nantes
• Centre National De La Rech Scientifique—Cnrs

Inventors

• Olive Daniel
• Bonneville Marc
• Scotet Emmanuel
• Harly Christelle
• Guillaume Yves

Classifications

• A61K40/4224

  Molecules with a "CD" designation not provided for elsewhere · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title